Table 1. Baseline characteristics of participants immediately before mass drug administration.
| Characteristic | Control (deferred MDA) villages | Intervention (early MDA) villages | Overall |
|---|---|---|---|
| People living in villages at month 0, n | 4,310 | 4,135 | 8,445 |
| Sex, n (%) | |||
| Male | 2,175 (50.5) | 2,099 (50.8) | 4,274 (50.6) |
| Female | 2,135 (49.5) | 2,036 (49.2) | 4,171 (49.4) |
| Age (years), median (IQR) | 19 (8, 36) | 21 (9, 37) | 20 (9, 36) |
| Weight (kg), median (IQR) | 41 (21, 51) | 44 (24, 52) | 43 (22, 51) |
| Height (cm), median (IQR) | 148 (123, 156) | 148 (127, 156) | 148 (124, 156) |
| Temperature (°C), median (IQR) | 36.8 (36.6, 37.1) | 36.9 (36.6, 37.1) | 36.9 (36.6, 37.1) |
| Fever, n (%) | n = 2,889 | n = 3,337 | n = 6,226 |
| Yes | 393 (13.6) | 462 (13.8) | 855 (13.7) |
| No | 2,496 (86.4) | 2,875 (86.2) | 5,371 (86.3) |
| Bednet use, n (%) | n = 2,816 | n = 2,804 | n = 5,620 |
| Regular | 2,377 (84.4) | 2,202 (78.5) | 4,579 (81.5) |
| Irregular | 364 (12.9) | 495 (17.7) | 859 (15.3) |
| Never use | 75 (2.7) | 107 (3.8) | 182 (3.2) |
| Baseline infection | n = 3,405 | n = 3,340 | n = 6,745 |
| Pf infection, n (%, 95% CI) | 246 (7.2, 6.4–8.1) | 171 (5.1, 4.4–5.9) | 417 (6.2, 5.6–6.8) |
| Pv infection, n (%, 95% CI) | 405 (11.9, 10.8–13.0) | 288 (8.6, 7.7–9.6) | 693 (10.3, 9.5–11.0) |
| Pf uPCR genomes/ml, geometric mean (95% CI) | 10,607 (8,146–13,812) | 3,363 (2,472–4,575) | 6,443 (5,260–7,892) |
CI, confidence interval; IQR, interquartile range; MDA, mass drug administration; Pf, P. falciparum; Pv, P. vivax; uPCR, ultrasensitive quantitative PCR.